Strategic Partnership in Alzheimer’s Research
The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis.
Significance of the Bio-Hermes-002 Study
Like its predecessor, Bio-Hermes-001, the Bio-Hermes-002 study sets an ambitious precedent, emphasizing inclusivity among diverse participant demographics. The study aims to ensure that at least 25% of its participants come from traditionally underrepresented groups, reflecting a commitment to equity in Alzheimer’s research.
Innovative Biomarkers
As part of this groundbreaking initiative, Lilly will supply two crucial PET imaging tracers, florbetapir F18 and flortaucipir F18. These tools are pivotal for examining the levels of amyloid and tau proteins—key indicators associated with Alzheimer’s progression. By analyzing these biomarkers, researchers hope to enhance understanding of the disease's buildup in the brain.
Feedback from Leaders in the Field
John Dwyer, President of GAP, expressed optimism about the collaboration, highlighting how working alongside Lilly will refine the methodologies used in clinical trials. He noted, “This study is critical for the eventual development of tests and trial designs that will improve lives, and we thank them for their partnership.”
Driving Towards Better Diagnosis
Mark Mintun, M.D., representing Eli Lilly, emphasized the organization's dedication to ensuring timely and accurate diagnoses for Alzheimer’s patients. According to him, the Bio-Hermes-002 study will further validate the efficacy of biomarkers in improving patient outcomes. He stated, “The study is critical to improve the timely diagnosis and treatment of appropriate patients.”
Utilization of Cutting-Edge Technology
Data obtained from the Bio-Hermes-002 study will be securely stored in the AD Workbench, developed by the Alzheimer’s Disease Data Initiative (ADDI). This global, cloud-based platform promotes collaborative research by providing secure access to data for scientists worldwide, thus broadening the scope of Alzheimer’s research significantly.
Engagement of Remarkable Partners
In addition to Lilly, the list of collaborators for the Bio-Hermes-002 study is expanding, with Biogen and several other esteemed organizations contributing to the project. These collaborations ensure that the study benefits from a diverse range of blood-based and digital biomarker assessments, enhancing the overall research capacity.
How to Get Involved
To learn more about the Bio-Hermes-002 study or to find out how to participate, interested individuals can visit the Global Alzheimer’s Platform Foundation website. As the research progresses, there will be numerous opportunities for various stakeholders to engage in this crucial work.
Frequently Asked Questions
What is the Bio-Hermes-002 study?
The Bio-Hermes-002 study is a collaborative initiative focused on enhancing the understanding of Alzheimer’s disease through advanced biomarker research.
What is the goal of the partnership between GAP and Eli Lilly?
The goal is to improve early diagnosis and treatment efficacy for Alzheimer’s patients by utilizing innovative biomarkers and increasing trial diversity.
How does the study ensure diversity in participants?
The study is committed to having at least 25% of its participants from traditionally underrepresented communities to promote inclusion in research.
What technologies are being used in the Bio-Hermes-002 study?
Key PET imaging tracers, florbetapir F18 and flortaucipir F18, will be utilized to measure amyloid and tau levels in study participants.
Where will the data from the study be stored?
The data will be stored in the AD Workbench, a secure platform facilitated by the Alzheimer’s Disease Data Initiative, which supports global research collaboration.
